Novartis Embarks On “Category Captainship” Pilot For Hypertension
Executive Summary
Novartis is initiating a new pilot program tagged "category captainship" focused on enhancing the drug maker's leadership position in the U.S. hypertension market
You may also be interested in...
Will Novartis’ Tekturna Be Buoyed By Category Captainship?
The performance of Novartis' newly approved hypertension therapy Tekturna will be a good test of the company's "category captainship" program, which has focused on establishing Novartis as a leader in targeted disease areas
Will Novartis’ Tekturna Be Buoyed By Category Captainship?
The performance of Novartis' newly approved hypertension therapy Tekturna will be a good test of the company's "category captainship" program, which has focused on establishing Novartis as a leader in targeted disease areas
Novartis’ “Captainship” Program Produces More Hypertension Market Share
Nearly a year after introducing its "category captainship" strategy to enhance its leadership position in the market, Novartis is reporting its most successful quarter in the hypertension market